SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in adults..

韩国首尔，2024年4月25日/PRNewswire/--韩国领先的生物技术公司Onconic Therapeutics今天宣布，韩国食品和药物安全部（MFDS）已批准JAQBO（zastaprazan柠檬酸盐）用于治疗成人糜烂性胃食管反流病（GERD）。。

JAQBO is a next-generation potassium competitive blocker (P-CAB) expected to become the new standard treatment in the market for gastric acid related diseases. JAQBO directly binds to proton pumps in a competitive manner to reduce gastric acid secretion. This novel mechanism allows quick onset of action regardless of the acidity level in the stomach, offering immediate symptom relief.

JAQBO是一种下一代钾竞争性阻滞剂（P-CAB），有望成为市场上与胃酸相关疾病的新标准治疗药物。JAQBO以竞争的方式直接与质子泵结合，以减少胃酸分泌。无论胃酸水平如何，这种新颖的机制都可以快速起效，从而立即缓解症状。

In addition, longer duration of acid suppression with no food effect could provide a new paradigm in GERD treatment..

此外，更长时间的酸抑制而不产生食物效应可以为GERD治疗提供新的范例。。

The MFDS approval of JAQBO is based on comprehensive results including the Phase III clinical trial across 28 sites in Korea. The study demonstrated JAQBO's effectiveness on erosive esophagitis, with a healing rate of 97.9% after 8 weeks of treatment. These results were presented at the United European Gastroenterology Week in October 2023..

JAQBO的MFDS批准基于综合结果，包括韩国28个地点的III期临床试验。该研究证明了JAQBO对糜烂性食管炎的有效性，治疗8周后治愈率为97.9%。这些结果发表在2023年10月的欧洲胃肠病学联合周上。。

Onconic Therapeutics aims to launch JAQBO this year after listing for National Healthcare Insurance Reimbursement in Korea. Domestic sales of JAQBO will be handled by Jeil Pharmaceutical, Onconic Therapeutics's parent company.

Onconic Therapeutics在韩国国家医疗保险报销上市后，计划今年推出JAQBO。JAQBO的国内销售将由Onconic Therapeutics的母公司Jeil Pharmaceutical负责。

In March 2023, JAQBO was licensed out to Livzon Pharmaceutical Group, the leading seller of PPIs in China for development and commercialization, in a deal value of $127.5 million for Greater China.

2023年3月，JAQBO被授权给Livzon Pharmaceutical Group，Livzon Pharmaceutical Group是中国PPI的主要销售商，用于开发和商业化，在大中华区的交易价值为1.275亿美元。

Onconic Therapeutics is committed to enhancing gastrointestinal treatment and improving patient outcomes by expanding additional indications.

Onconic Therapeutics致力于通过扩大其他适应症来增强胃肠道治疗并改善患者预后。

About Onconic Therapeutics

关于肿瘤治疗学

Onconic Therapeutics is a Korean leader in developing novel drugs. With a focus on innovative research and clinical excellence, Onconic Therapeutics is dedicated to improving patient outcomes and providing quality healthcare solutions for cancer and gastrointestinal disorders.

Onconic Therapeutics是韩国开发新药的领导者。Onconic Therapeutics专注于创新研究和临床卓越，致力于改善患者预后，并为癌症和胃肠道疾病提供优质的医疗保健解决方案。